An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer

An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer

Abstract Background Surveilling recurrent urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. Objective To audit the...

Full description

Bibliographic Details
Main Authors: Madhusudan Koya, Sue Osborne, Christophe Chemaslé, Sima Porten, Anne Schuckman, Andrew Kennedy-Smith
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Urology
Subjects:
Bladder cancer
Cystoscopy
Recurrence
Genomic rule-out test
Online Access:https://doi.org/10.1186/s12894-020-0583-0

Internet

https://doi.org/10.1186/s12894-020-0583-0

Similar Items